Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Cell Reports(2022)10.1016/j.celrep.2022.110993Source: DataRank Database

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 164 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access164 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (27 grants)Impact (FWCI 10.34)OA: goldTopics (64)Linked Datasets (2)DataCite Reuse (2)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Oluwadara Coker ORCID,Alexey V. Sorokin ORCID,Katerina A. Fella,Haley Barnes ORCID,Edmond Wong ORCID

Live enrichment

PubMed:35732135 PMC:PMC9809542 OpenAlex:https://openalex.org/W4283259595

National Cancer Institute

Grant: U54CA224068

National Cancer Institute

Grant: P50 CA127003

Entertainment Industry Foundation

Grant: SU2C-AACR-DT22-17

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: U54 CA224065

NCI NIH HHS

Grant: P50 CA221707

NCI NIH HHS

Grant: T32 CA217789

NCI NIH HHS

Grant: R01 CA262805

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5U54CA224068-03

An integrated translational approach to overcome drug resistance

National Institutes of Health

Grant: 5P50CA127003-12

Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer

Shire

Grant: unidentified

unidentified

National Institutes of Health

Grant: 1U54CA224065-01

University of Texas PDX Development and Trial Center

AbbVie

Shire

Spectrum Pharmaceuticals

Les Laboratories Pierre Fabre

Servier

American Association for Cancer Research

National Institutes of Health

Ipsen Biopharmaceuticals

Shionogi

Mirati Therapeutics

Novartis

Daiichi-Sankyo

Gilead Sciences

Revolution Medicines

FWCI

10.34

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.celrep.2022.110993

publisherhttps://doi.org/10.1016/j.celrep.2022.110993

publisherhttps://api.elsevier.com/content/article/PII:S2211124722007793?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124722007793?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35732135

Fields of Study

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicineAnimalsCell Line, TumorErbB ReceptorsFeedbackHumansMiceMitogen-Activated Protein KinasesMutationNeoplasmsProto-Oncogene Proteins p21(ras)Signal Transduction

MeSH Terms

AnimalsFeedbackHumansMutationNeoplasmsSignal TransductionProto-Oncogene Proteins p21(ras)Mitogen-Activated Protein KinasesCell Line, TumorMiceErbB Receptors

Keywords

KRASMAPK/ERK pathwayReceptor tyrosine kinaseEpidermal growth factor receptorKinaseCancer researchTyrosine kinaseSignal transductionGrowth factor receptorEpidermal growth factorBiologyCell biologyPharmacologyReceptorMedicineColorectal cancerCancerInternal medicineBiochemistryAdaptive ResistanceKrasg12cCp: CancerAdagrasibSotorasibArticleFeedbackErbB ReceptorsProto-Oncogene Proteins p21(ras)MiceCell Line, TumorNeoplasmsMutationAnimalsHumansMitogen-Activated Protein Kinases

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

10.6084/m9.figshare.26027462.v1figshare

Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

10.6084/m9.figshare.26027462figshare